前立腺癌の分子標的治療(1) (第56回日本泌尿器科学会中部総会)

HANDLE Web Site オープンアクセス

書誌事項

タイトル別名
  • Molecular targeted therapy for prostate cancer
  • 前立腺癌の分子標的治療(1)
  • ゼンリツセンガン ノ ブンシ ヒョウテキ チリョウ 1

この論文をさがす

抄録

Androgen plays an important role in the growth of prostate cancer, but the molecular mechanism that underlies the development of resistance to anti-androgen therapy remains unknown. In this paper, we review the role of cell cycle regulators and steroid receptor co-activators for prostate cancer growth and survival. Cyclin E has been shown to increase the transactivation activity of the human androgen receptor and the proliferation of prostate cancer cells. On the other hand, p27 using an adenovirus vector was shown to reduce the size of tumors of human prostate cancer xenografts. Steroid receptor coactivator-3 (SRC-3) is often over-expressed in prostate cancers. Our results indicate that overexpression of SRC-3 can modulate the AKT (protein kinase B) signaling pathway and stimulate cell growth in prostate cancer. In contrast, down-regulation of SRC-3 expression by small interfering RNA suppresses cell growth.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 54 (1), 57-61, 2008-01

    泌尿器科紀要刊行会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ